A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
08 09 2020
Historique:
received: 05 05 2020
accepted: 05 08 2020
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 24 9 2020
Statut: epublish

Résumé

The SARS-CoV-2 pandemic has shown how a rapid rise in demand for patient and community sample testing can quickly overwhelm testing capability globally. With most diagnostic infrastructure dependent on specialized instruments, their exclusive reagent supplies quickly become bottlenecks, creating an urgent need for approaches to boost testing capacity. We address this challenge by refocusing the London Biofoundry onto the development of alternative testing pipelines. Here, we present a reagent-agnostic automated SARS-CoV-2 testing platform that can be quickly deployed and scaled. Using an in-house-generated, open-source, MS2-virus-like particle (VLP) SARS-CoV-2 standard, we validate RNA extraction and RT-qPCR workflows as well as two detection assays based on CRISPR-Cas13a and RT-loop-mediated isothermal amplification (RT-LAMP). In collaboration with an NHS diagnostic testing lab, we report the performance of the overall workflow and detection of SARS-CoV-2 in patient samples using RT-qPCR, CRISPR-Cas13a, and RT-LAMP. The validated RNA extraction and RT-qPCR platform has been installed in NHS diagnostic labs, increasing testing capacity by 1000 samples per day.

Identifiants

pubmed: 32900994
doi: 10.1038/s41467-020-18130-3
pii: 10.1038/s41467-020-18130-3
pmc: PMC7479142
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

4464

Subventions

Organisme : Department of Health
ID : NIHR-RP-011-048
Pays : United Kingdom

Commentaires et corrections

Type : ErratumIn

Références

World Health Organisation. Coronavirus disease 2019 (Covid-19) situation report 51. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10 . Accessed 4 Feb 2020.
Gorbalenya, A. E. et al. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5. https://doi.org/10.1038/s41564-020-0695-z (2020).
Dong, E., Du, H. & Gardner, L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect. Dis. https://doi.org/10.1016/S1473-3099(20)30120-1 (2020).
Freemont, P. S. Synthetic biology industry: data-driven design is creating new opportunities in biotechnology. Emerg. Top. Life Sci. 3, 651–657 (2019).
doi: 10.1042/ETLS20190040 pmcid: 7289019
Pasloske, B. L., Walkerpeach, C. R., Dawn Obermoeller, R., Winkler, M. & DuBois, D. B. Armored RNA technology for production of ribonuclease-resistant viral RNA controls and standards. J. Clin. Microbiol. 36, 3590–3594 (1998).
doi: 10.1128/JCM.36.12.3590-3594.1998 pubmed: 9817878 pmcid: 105245
Cheng, Y., Niu, J., Zhang, Y., Huang, J. & Li, Q. Preparation of his-tagged armored RNA phage particles as a control for real-time reverse transcription-PCR detection of severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 44, 3557–3561 (2006).
doi: 10.1128/JCM.00713-06 pubmed: 17021082 pmcid: 1594775
Yu, X. F., Pan, J. C., Ye, R., Xiang, H. Q., Kou, Y. & Huang, Z. C. Preparation of armored RNA as a control for multiplex real-time reverse transcription-PCR detection of influenza virus and severe acute respiratory syndrome coronavirus. J. Clin. Microbiol. 46, 837–841 (2008).
doi: 10.1128/JCM.01904-07 pubmed: 18160451
Jung, Y. J. et al. Comparative analysis of primer-probe sets for the laboratory confirmation of SARS-CoV-2. Preprint at https://doi.org/10.1101/2020.02.25.964775 (2020).
Centers for Disease Control and Prevention Division of Viral Diseases. 2019-Novel Coronavirus (2019-nCoV) Real-time Rt-PCR Panel Primers and Probes (Centers for Disease Control and Prevention Division of Viral Diseases) (2020).
Metsky, H. C., Freije, C. A., Kosoko-Thoroddsen, T.-S. F., Sabeti, P. C. & Myhrvold, C. CRISPR-based COVID-19 surveillance using a genomically-comprehensive machine learning approach. Preprint at https://doi.org/10.1101/2020.02.26.967026 (2020).
Zhang, Y. et al. Rapid molecular detection of SARS-CoV-2 (COVID-19) virus RNA using colorimetric LAMP. Preprint at https://doi.org/10.1101/2020.02.26.20028373 (2020).
Department of Health and Social Care and Public Health England. Coronavirus cases in the UK: daily updated statistics–GOV.UK. https://www.gov.uk/guidance/coronavirus-covid-19-information-for-the-public . Accessed 8 July 2020.
de Martín Garrido, N., Crone, M. A., Ramlaul, K., Simpson, P. A., Freemont, P. S. & Aylett, C. H. S. Bacteriophage MS2 displays unreported capsid variability assembling T = 4 and mixed capsids. Mol. Microbiol. 113, 143–152 (2020).
doi: 10.1111/mmi.14406 pubmed: 31618483
Mikel, P., Vasickova, P. & Kralik, P. One-plasmid double-expression His-tag system for rapid production and easy purification of MS2 phage-like particles. Sci. Rep. 7, 1–12 (2017).
doi: 10.1038/s41598-017-17951-5
Vogels, C. B. F. et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets. Nat. Microbiol. (2020).
Gootenberg, J. S., Abudayyeh, O. O., Kellner, M. J., Joung, J., Collins, J. J. & Zhang, F. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science 360, 439–444 (2018).
doi: 10.1126/science.aaq0179 pubmed: 29449508 pmcid: 5961727
Tanner, N. A., Zhang, Y. & Evans, T. C. Visual detection of isothermal nucleic acid amplification using pH-sensitive dyes. Biotechniques 58, 59–68 (2015).
doi: 10.2144/000114253 pubmed: 25652028
Pan, Y., Zhang, D., Yang, P., Poon, L. L. M. & Wang, Q. Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 20, 411–412 (2020).
doi: 10.1016/S1473-3099(20)30113-4 pubmed: 32105638 pmcid: 7128099
Joung, J. et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. Preprint at https://doi.org/10.1101/2020.05.04.20091231 (2020).
Foundation for Innovative New Diagnostics. Covid-19 diagnostics. https://www.finddx.org/covid-19/ . Accessed 2 April 2020.
Sheridan, C. Fast, portable tests come online to curb coronavirus pandemic. Nat. Biotechnol. https://doi.org/10.1038/d41587-020-00010-2 (2020).
Xie, Q. et al. Effect of large-scale testing platform in prevention and control of the COVID-19 pandemic: an empirical study with a novel numerical model. Preprint at https://doi.org/10.1101/2020.03.15.20036624 (2020).
Open Wet Ware. SPRI bead mix. https://openwetware.org/wiki/SPRI_bead_mix#Example_with_RNA_standard . Accessed 2 April 2020.
Aitken, J. et al. Scalable and robust SARS-CoV-2 testing in an academic center. Nat. Biotechnol. 38, 927–931 (2020).
doi: 10.1038/s41587-020-0588-y pubmed: 32555528
Broughton, J. P. et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 38, 870–874 (2020).
doi: 10.1038/s41587-020-0513-4 pubmed: 32300245
Ackerman, C. M. et al. Massively multiplexed nucleic acid detection using Cas13. Nature https://doi.org/10.1038/s41586-020-2279-8 (2020).
Mohon, A. N. et al. Development and validation of direct RT-LAMP for SARS-CoV-2. Clin. Sect. Microbiol. 78, 1–26 (2020).
Metz, S. W. et al. Dengue virus-like particles mimic the antigenic properties of the infectious dengue virus envelope. Virol. J. 15, 1. https://doi.org/10.1186/s12985-018-0970-2 (2018).
Stevenson, J., Hymas, W. & Hillyard, D. The use of armored RNA as a multi-purpose internal control for RT-PCR. J. Virol. Methods 150, 73–76 (2008).
doi: 10.1016/j.jviromet.2008.02.007 pubmed: 18395804 pmcid: 7119664
Hillson, N. et al. Building a global alliance of biofoundries. Nat. Commun. 10, 1. https://doi.org/10.1038/s41467-019-10079-2 (2019).
Der, B. S. et al. DNAplotlib: Programmable Visualization of Genetic Designs and Associated Data. ACS Synthetic Biology 6, 1115–1119 (2017).
doi: 10.1021/acssynbio.6b00252 pubmed: 27744689

Auteurs

Michael A Crone (MA)

London Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.
Section of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, London, SW7 2AZ, UK.
UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK.

Miles Priestman (M)

London Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.
Section of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, London, SW7 2AZ, UK.

Marta Ciechonska (M)

London Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.
Section of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, London, SW7 2AZ, UK.

Kirsten Jensen (K)

London Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.
Section of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, London, SW7 2AZ, UK.
UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK.

David J Sharp (DJ)

UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK.
Department of Brain Sciences, Imperial College London, Hammersmith Hospital, Du Cane Road, London, W12 0NN, UK.

Arthi Anand (A)

Histocompatibility and Immunogenetics Laboratories, Department of Infection and Immunity, North West London Pathology, London, UK.
Imperial College Healthcare NHS Trust, Hammersmith Hospital, Du Cane Road, London, W12 0HS, UK.

Paul Randell (P)

Department of Infection and Immunity, North West London Pathology, London, UK.
Imperial College Healthcare NHS Trust, Charing Cross Hospital, Fulham Palace Road, Hammersmith, London, W6 8RF, UK.

Marko Storch (M)

London Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK.
Section of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, London, SW7 2AZ, UK.

Paul S Freemont (PS)

London Biofoundry, Imperial College Translation and Innovation Hub, White City Campus, 80 Wood Lane, London, W12 0BZ, UK. p.freemont@imperial.ac.uk.
Section of Structural and Synthetic Biology, Department of Infectious Disease, Imperial College London, London, SW7 2AZ, UK. p.freemont@imperial.ac.uk.
UK Dementia Research Institute Centre for Care Research and Technology, Imperial College London, London, UK. p.freemont@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH